Needle-Free light therapy shows promise for common skin cancer

NCT ID NCT04552990

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new way to treat basal cell carcinoma, a common skin cancer. Instead of surgery, doctors used a jet-injection device to deliver a drug called ALA into the tumor, then activated it with red light. The trial included 16 adults with small, low-risk BCCs and aimed to see if the treatment was safe and caused only mild side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
aminolevulinic acid (ALA)
What this could lead to
If successful, this could offer a less invasive treatment option for certain basal cell carcinomas, potentially reducing the need for surgery.
What could go wrong
This is a very small, early-phase trial with only 16 participants, focused on safety. It is not designed to prove effectiveness, and the approach may not work for all types of BCC or may cause skin reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BASAL CELL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.